4
Tetrahedron
o
1
ethoxy)isoindoline-1,3-dione, 3g, M.P.= 85-87 C, H NMR
(400 M HZ, CDCl3): 7.80-7.82 (m, 2 H), 7.73-7.75 (m, 2 H),
4.35-4.46 (m, 1 H), 4.10-4.23 (m, 1 H), 2.65 (m, 1 H), 2.25-2.26
(m, 1 H), 1.98-2.00 (m, 1 H), 1.81-1.83 (m, 1 H), 1.53-1.60 (m, 2
H), 1.44 (m, 7 H), 1.26-1.34 (m, 3 H), 1.11-1.19 (m, 10 H); 13C
NMR (100 MHz, CDCl3): 163.8, 134.1, 128.9, 123.1, 94.9, 90.8,
89.8, 59.9, 59.1, 40.4, 40.2, 39.9, 39.5, 33.9, 33.7, 33.6, 32.7,
25.4, 24.0, 23.5, 20.0, 17.0; IR (cm-1): 2971, 2933, 1790, 1731,
1461, 1374, 1361, 1185, 1131, 1082, 1045, 876, 733; HRMS
(ESI) m/z: calcd for C24H32N2O4Na+: [M+Na+]= 435.2260; found:
435.2263.
ACCEPTED MANUSCRIPT
(400 M HZ, CDCl3): 7.68-7.77 (m,5 H), 7.21-7.34 (m, 3 H), 5.50-
5.52 (m, 1 H), 4.70-4.74 (m, 1 H), 4.57-4.60 (m, 1 H), 1.06-1.49
(m, 16 H), 0.78 (m, 2 H); 13C NMR (100 MHz, CDCl3): 162.9,
137.7, 134.2, 132.3, 128.6, 126.4, 123.2, 81.3, 78.7, 60.0, 40.3,
34.0, 33.1, 20.2, 17.0; IR (cm-1): 3062, 2973, 2932, 1791, 1732,
1468, 1187, 1131, 1081, 1034, 876, 759; HRMS (ESI) m/z: calcd
for C25H29ClN2O4Na+: [M+Na+]= 479.1714; found: 479.1710.
2-(2-(3-bromophenyl)-2-(2,2,6,6-tetramethylpiperidin-1-yloxy)
ethoxy)isoindoline-1,3-dione, 3h, oil, 1H NMR (400 M HZ,
CDCl3): 7.70-7.80 (m, 4 H), 7.63 (s, 1 H), 7.38-7.44 (m, 2 H),
7.20-7.24 (m, 1 H), 5.07-5.10 (m, 1 H), 4.69-4.71 (m, 1 H), 4.45-
4.49 (m, 1 H), 1.05-1.47 (m, 16 H), 0.74 (m, 2 H); 13C NMR (100
MHz, CDCl3): 163.0, 142.5, 134.3, 130.9, 130.7, 129.6, 128.7,
126.5, 123.3, 122.1, 82.6, 79.6, 60.1, 40.3, 33.9, 20.2, 17.0; IR
(cm-1): 3070, 2972, 1790, 1730, 1570, 1374, 1361, 1186, 1131,
1081, 876, 785; HRMS (ESI) m/z: calcd for C25H29BrN2O4Na+:
[M+Na+]= 523.1208; found: 523.1230.
4-(2-((1,3-dioxoisoindolin-2-yl)oxy-1-((2,2,6,6-tetramethyl-
o
1
piperidin-1-yl)oxy)ethyl)benzonitrile, 3n, M.P.=119-120 C, H
NMR (400 M HZ, CDCl3): 7.79-7.81 (m, 4 H), 7.63-7.75 (m, 4
H), 5.14-5.17 (m, 1 H), 4.70-4.73 (m, 1 H), 4.47-4.52 (m, 1 H),
1.43-1.49 (m, 5 H), 1.05-1.40 (m, 10 H), 0.73 (m, 3 H); 13C NMR
(100 MHz, CDCl3): 162.9, 145.4, 134.4, 131.7, 128.4, 123.3,
118.7, 111.3, 82.6, 79.2, 60.0, 40.1, 33.8, 20.1, 16.8; IR(cm-1):
2937, 2229, 1791, 1733, 1467, 1374, 1187, 1130, 1020, 996, 877,
840; HRMS (ESI) m/z: calcd for C26H29N3O4Na+: [M+Na+]=
470.2056; found: 470.2086.
2-(2-(3-chlorophenyl)-2-((2,2,6,6-tetramethylpiperidin-1-yl)oxy)
ethoxy)isoindoline-1,3-dione, 3i, oil, 1H NMR (400 MHZ,
CDCl3): 7.72-7.79 (m, 4 H), 7.48 (s, 1 H), 7.37-7.39 (m, 1 H),
7.23-7.30 (m, 2 H), 5.08-5.11 (m, 1 H), 4.69-4.71 (m, 1 H), 4.45-
4.49 (m, 1 H), 1.05-1.47 (m, 16 H), 0.74 (m, 2 H); 13C NMR (100
MHz, CDCl3): 163.1, 142.2, 134.4, 133.8, 129.3, 128.7, 128.0,
127.8, 126.1, 123.3, 82.7, 79.7, 65.8, 60.1, 40.3, 34.0, 20.2, 17.0,
15.2; IR (cm-1): 2973, 2932, 1791, 1732, 1468, 1362, 1187, 1131,
1081, 1018, 998, 876, 786, 699; HRMS (ESI) m/z: calcd for
C25H29ClN2O4H+: [M+H+]=457.1894; found: 457.1896.
2-(2-(tert-butylperoxy)-2-(4-methoxyphenyl)ethoxy)isoindoline-
1,3-dione, 3o, oil, H NMR (400 M HZ, CDCl3): 7.71-7.81 (m, 4
1
H), 7.35-7.38 (m, 2 H), 6.87 (d, J = 8.0 Hz, 2 H), 5.30-5.33 (m, 1
H), 4.62-4.65 (m, 1 H), 4.44-4.48 (m, 1 H), 3.77 (s, 3 H), 1.17 (s,
9 H); 13C NMR (100 MHz, CDCl3): 163.1, 159.7, 134.3, 128.9,
128.8, 123.3, 113.7, 82.8, 80.6, 78.2, 55.1, 28.5, 26.2; IR (cm-1):
2977, 2933, 1790, 1731, 1612, 1407, 1364, 1249, 1186, 1130,
1018, 996, 877, 830, 701; HRMS (ESI) m/z: calcd for
C21H23NO6Na+: [M+ Na+]= 408.1423; found: 408.1415.
2-(2-(naphthalen-2-yl)-2-((2,2,6,6-tetramethylpiperidin-1-yl)oxy)
2-(2-phenylallyloxy)isoindoline-1,3-dione, 3p, oil, 1H NMR (400
M HZ, CDCl3): 7.81-7.83 (m, 2 H), 7.72-7.75 (m, 2 H), 7.66-7.68
(m, 2 H), 7.38-7.40 (m, 2 H), 7.33-7.37 (m, 1 H), 5.73 (s, 1 H),
5.51 (s, 1 H), 5.09 (s, 2 H); 13C NMR (100 MHz, CDCl3): 163.4,
141.2, 137.8, 134.4, 128.4, 127.9, 126.2, 123.4, 119.6, 79.7; IR
(cm-1): 3060, 2970, 1790, 1731, 1645, 1465, 1180, 1130, 1080,
1034, 876.
ethoxy)isoindoline-1,3-dione, 3j, M.P.=108-109 oC, 1H NMR
(400 MHZ, CDCl3): 7.92 (s, 1 H), 7.76-7.86 (m, 3 H), 7.68-7.71
(m, 2 H), 7.58-7.62 (m, 3 H), 7.39-7.46 (m, 2 H), 5.28-5.31 (m, 1
H), 4.80-4.84 (m, 1 H), 4.58-4.62 (m, 1 H), 1.05-1.49 (m, 16 H),
0.69 (m, 2 H); 13C NMR (100 MHz, CDCl3): 163.0, 137.4, 132.9,
128.0, 127.7, 127.5, 127.3, 125.7, 125.6, 125.4, 123.1, 83.5, 79.7,
40.3, 17.0; IR (cm-1): 3058, 2976, 2932, 1788, 1734, 1465, 1369,
1183, 1129, 994, 874, 818, 742; HRMS (ESI) m/z: calcd for
C29H32N2O4H+:[M+H+]=473.2440; found: 473.2440.
Acknowledgments
2-(1-phenyl-1-(2,2,6,6-tetramethylpiperidin-1-yloxy)propan-2-
yloxy)isoindoline-1,3-dione, 3k, oil, 1H NMR (400 M HZ,
CDCl3): 7.79-7.82 (m, 2 H), 7.71-7.74 (m, 2 H), 7.62-7.64 (m, 2
H), 7.28-7.35 (m, 3 H), 5.05-5.11 (m, 1 H), 4.83 (d, J = 3.2 Hz, 1
H), 1.27-1.40 (m, 15 H), 1.10 (m, 2 H), 1.00 (m, 2 H), 0.46 (m, 2
H); 13C NMR (100 MHz, CDCl3): 163.7, 138.6, 134.2, 129.8,
129.0, 127.5, 123.1, 89.8, 85.4, 60.4, 59.5, 40.6, 34.4, 33.9, 20.2,
17.0, 16.4; IR (cm-1): 3070, 2932, 1791, 1731, 1467, 1455, 1376,
1362, 1187, 1131, 1081, 1016, 878; HRMS (ESI) m/z: calcd for
C26H32N2O4Na+: [M+Na+]= 459.2260; found: 459.2260.
We thank the National Science Foundation of China NSF
21402066, Natural Science Foundation of Jiangsu Province
(BK20140139) and the Fundamental Research Funds for the
Central Universities (JUSRP11419) for financial support.
Financial support from MOE&SAFEA for the 111 project
(B13025) is also gratefully acknowledged
.
References and notes
1. For selected reviews, see: (a) The Chemistry of Double Bonded Functional
Groups; Patai, S., Ed.; Wiley: Chichester, U.K., 1997. (b) Takacs, J. M.;
Jiang, X. Curr. Org. Chem. 2003, 7, 369. (c) Cornell, C. N.; Sigman, M. S.
Inorg. Chem. 2007, 46, 1903. (d) Muzart, J. Tetrahedron 2007, 63, 7505.
(e) Flynn, A. B.; Ogilvie, W. W. Chem.Rev. 2007, 107, 4698. (f) Tang, S.;
Liu, K.; Liu, C.; Lei, A. Chem. Soc. Rev. 2015, 44, 1070.
2-(1,2-diphenyl-2-(2,2,6,6-tetramethylpiperidin-1-yloxy)ethoxy)
1
isoindoline-1,3-dione, 3l, dr=1.3:1, oil, H NMR (400 M HZ,
CDCl3): 7.61-7.73 (m, 4 H), 7.06-7.34 (m, 10 H), 6.01-6.20 (d, J
= 5.2, 6.8 Hz, 1 H), 5.04-5.45 (d, J = 6.8, 5.2 Hz, 1 H), 1.26-1.67
(m, 15 H), 1.01-1.02 (m, 3 H); 13C NMR (100 MHz, CDCl3):
163.5, 138.9, 137.3, 136.1, 135.3, 134.1, 128.2, 127.1, 123.2,
123.1, 89.8, 88.8, 88.6, 88.0, 60.7, 40.9, 34.5, 33.8, 31.5, 30.1,
29.7, 22.7, 20.4, 17.1; IR (cm-1): 2930, 1790, 1737, 1455, 1374,
1187, 1132, 976, 876, 699; HRMS (ESI) m/z: calcd for
C31H34N2O4Na+: [M+Na+] = 521.2416; found: 521.2417.
2. For selected reviews, see: (a) Sibbald, P. A. Palladium-catalyzed oxidative
difunctionalization of alkenes: New reactivity and new mechanisms,
ProQuest, UMI Dissertation Publishing, 2011. (b) Jacques, B.; Muinz K.
Catalyzed carbon-heteroatom bond formation (Ed.: A. K. Yudin), Wiley,
VCH, 2011. (c) McDonald, R. I.; Liu, G.; Stahl, S. S. Chem. Rev. 2011,
111, 2981. (d) Jensen, K. H.; Sigman, M, S. Org. Biomol Chem. 2008, 6,
4083. (e) Schultz, D. M.; Wolfe, J. P. Synthesis. 2012, 44, 351. (f) Mai, W.;
2-(3-(2,2,6,6-tetramethylpiperidin-1-yloxy)bicycle[2.2.1]heptan-
o
1
2-yloxy)isoindoline-1,3-dione, 3m, M.P.= 104-106 C, H NMR